{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:15:52Z","timestamp":1783970152871,"version":"3.55.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.beha.2025.101659","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:12:11Z","timestamp":1759558331000},"page":"101659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CAR-T cell therapy for multiple myeloma: An update on the current state and future potential"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-3462","authenticated-orcid":false,"given":"Prateek","family":"Pophali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacalyn","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.beha.2025.101659_bib3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.beha.2025.101659_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2025.101659_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2025.101659_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"issue":"18","key":"10.1016\/j.beha.2025.101659_bib10","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2025.101659_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101659_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"10297","key":"10.1016\/j.beha.2025.101659_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib17","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.beha.2025.101659_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib21","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2024.42.16_suppl.7505","article-title":"Efficacy and safety of ciltacabtagene autoleucel \u00b1 lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D","volume":"42","author":"Arnulf","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101659_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib23","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2023-182141","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101659_bib24","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib25","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1182\/blood-2023-190583","article-title":"A real-world comparison of idecabtagene vicleucel and ciltacabtagene autoleucel CAR-T therapy: a single center experience for relapsed\/refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101659_bib26","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.beha.2025.101659_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103138","article-title":"Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial","volume":"81","author":"Ghobadi","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.beha.2025.101659_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib31","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2023-187565","article-title":"Alternative lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma","volume":"142","author":"Midha","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib33","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101659_bib34","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.beha.2025.101659_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2025.101659_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib37","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2024.42.16_suppl.7520","article-title":"Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy","volume":"42","author":"Bansal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101659_bib38","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.beha.2025.101659_bib40","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101659_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2025.101659_bib44","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib47","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8063","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma (CAMMOUFLAGE trial)","volume":"41","author":"Berdeja","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101659_bib50","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1084\/jem.178.3.1023","article-title":"The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell","volume":"178","author":"Billadeau","year":"1993","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101659_bib51","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2025.101659_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"issue":"20","key":"10.1016\/j.beha.2025.101659_bib53","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2025.101659_bib54","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib56","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.beha.2025.101659_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.beha.2025.101659_bib59","first-page":"2296","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"Reply The New England journal of medicine"},{"issue":"14","key":"10.1016\/j.beha.2025.101659_bib60","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti\u2013G protein\u2013coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-Targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib62","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib63","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.beha.2025.101659_bib65","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.beha.2025.101659_bib66","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib67","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O'Neal","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib68","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2025.101659_bib71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.beha.2025.101659_bib73","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib74","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib75","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib76","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.beha.2025.101659_bib77","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101659_bib79","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.beha.2025.101659_bib80","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.beha.2025.101659_bib81","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib82","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2022.2030476","article-title":"A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.beha.2025.101659_bib84","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"Journal of Cellular Immunotherapy"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib86","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.beha.2025.101659_bib87","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Therapeut"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101659_bib89","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101659_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"Camma 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib91","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101659_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206715","article-title":"\"Waitlist mortality\" is high for myeloma patients with limited access to BCMA therapy","volume":"13","author":"Ahmed","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.beha.2025.101659_bib95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2025.101659_bib97","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.beha.2025.101659_bib98","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2025.101659_bib99","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2025.101659_bib100","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"20","key":"10.1016\/j.beha.2025.101659_bib101","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2025.101659_bib102","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2025.101659_bib103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib104","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.beha.2025.101659_bib105","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101659_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.beha.2025.101659_bib107","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101659_bib108","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.beha.2025.101659_bib109","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.beha.2025.101659_bib110","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:20:52Z","timestamp":1764318052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521692625000659"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101659","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for multiple myeloma: An update on the current state and future potential","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101659"}}